Mr. Heraldo Carvalho Marchezini serves as the Chief Executive Officer and Member of The Executive Board at Biomm S.A. Mr. Marchezini served as Senior Vice President of Latin America Region at Sanofi, holdi...

取締役

名称	ポジション	在職期間	報酬	所有権
Luiz Novelli Viana	Director	10.5yrs	データなし	データなし
Eduardo Buarque de Almeida	Director	no data	データなし	データなし
Walfrido dos Mares Guia Neto	Director	10.5yrs	データなし	6.42% R$ 113.1m
Italo Gaetani	Director	10.5yrs	データなし	3.54% R$ 62.4m
Claudio Lottenberg	Chairman of the Board	6.2yrs	データなし	データなし
Andre Emrich	Director	2.5yrs	データなし	データなし
Frederico Dos Mares Guia	Alternate Director	4.2yrs	データなし	データなし
Pedro Miguel Mateo	Alternate Director	4.2yrs	データなし	データなし
Anna Emilia Sousa Gaetani	Alternate Director	4.2yrs	データなし	データなし
Pedro Augusto Prado	Director	less than a year	データなし	データなし
Laura Castanheira	Director	less than a year	データなし	データなし
Marcio Pochmann	Director	less than a year	データなし	データなし

4.2yrs

平均在職期間

経験豊富なボード: BIOM3の取締役会は経験豊富であると考えられます ( 4.2年の平均在任期間)。

Biomm マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

No independent directors

No independent directors

Recent updates

New major risk - Shareholder dilution

Is Biomm (BVMF:BIOM3) Weighed On By Its Debt Load?

First quarter 2024 earnings released: R$0.15 loss per share (vs R$0.22 loss in 1Q 2023)

Biomm S.A.'s (BVMF:BIOM3) 69% Price Boost Is Out Of Tune With Revenues

Full year 2023 earnings released

Biomm S.A.'s (BVMF:BIOM3) Share Price Is Matching Sentiment Around Its Revenues

New major risk - Shareholder dilution

Biomm S.A. to Report Q3, 2024 Results on Nov 13, 2024

Third quarter 2023 earnings released: R$0.27 loss per share (vs R$0.34 loss in 3Q 2022)

Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt

New major risk - Share price stability

Biomm S.A. to Report Q3, 2023 Results on Nov 13, 2023

Second quarter 2023 earnings released: R$0.25 loss per share (vs R$0.33 loss in 2Q 2022)

New major risk - Share price stability

We Think Biomm (BVMF:BIOM3) Has A Fair Chunk Of Debt

Positive Sentiment Still Eludes Biomm S.A. (BVMF:BIOM3) Following 26% Share Price Slump

Full year 2022 earnings released: R$1.26 loss per share (vs R$1.19 loss in FY 2021)

Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt

No independent directors

Biomm (BVMF:BIOM3) Is Making Moderate Use Of Debt

Second quarter 2022 earnings released: R$0.33 loss per share (vs R$0.20 loss in 2Q 2021)

Biomm (BVMF:BIOM3) Is Carrying A Fair Bit Of Debt

Biomm S.A. to Report Q2, 2022 Results on Aug 11, 2022

No independent directors

Biomm S.A. to Report Q1, 2022 Results on May 13, 2022

Biomm S.A. to Report Q1, 2022 Results on May 13, 2022

Full year 2021 earnings released

We Think Biomm (BVMF:BIOM3) Has A Fair Chunk Of Debt

Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days

Here's Why Biomm (BVMF:BIOM3) Can Afford Some Debt

Full year 2020 earnings released

Biomm (BVMF:BIOM3) Shareholders Have Enjoyed An Impressive 173% Share Price Gain

New 90-day low: R$14.95

New 90-day low: R$15.55

Do Institutions Own Biomm S.A. (BVMF:BIOM3) Shares?

New 90-day low: R$15.86

Is Biomm (BVMF:BIOM3) A Risky Investment?

Bio-Thera Solutions Announces Licensing Agreement with Biomm S.A. to Distribute and Market BAT1706 in Brazil

New 90-day high: R$17.10

Biomm S.A. to Report Q3, 2020 Results on Nov 06, 2020

New 90-day low - R$15.85

CEO（最高経営責任者

在職期間

取締役

平均在職期間

マネジメント基準チェック /14